Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors

Abstract excerpt

Abstract Mutations in the isocitrate dehydrogenase-1 and -2 (IDH1/2) genes were first identified in glioma and acute myeloid leukemia (AML), and subsequently found in multiple other tumor types. These neomorphic mutations convert the normal product of enzyme, α-ketoglutarate (αKG), to the oncometabolite 2-hydroxyglutarate (2HG). Our group recently demonstrated that 2HG suppresses the high-fidelity homologous...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cell death mechanisms and regulation
• Share to DNA Repair Mechanisms
• Share to PARP inhibition in cancer therapy